MET and hepatocellular carcinoma: To further research the connection between the CS and immunotherapy, we summarized the targets of immune related therapy for HCC, including PD1, PDL1, CTLA‐4, VEGF, VEGFR, KIT, PDGFR, HGFR, CDHR and RAF.